A new approach to the treatment of optic nerve atrophy as an inflammatory disease

The aim of the study was to conduct an antibacterial treatment of optic nerve atrophy against the microflora of the conjunctiva of the eye (microbiota) in small doses. The treatment was performed in 65 patients with optic nerve atrophy. The age of patients ranged from 12 to 75 years. The patients underwent general ophthalmological studies before and after the treatment. A special place was occupied by the perimetry before and after the treatment. Before the treatment, a bacteriological analysis of the conjunctiva of the eye was determined in patients to establish a nature of the microbial population (microbiota). Then, considering this population (microbiota) a specific drug was selected. The drug was taken in such a minimum concentration in order not to "kill" the existing microflora but only to weaken it. When this dose was exceeded no improvement in visual indices has been observed. This drug was administered subcutaneously. The effectiveness of the therapy was determined 8 and 30 days and 3 months after the end of the treatment; then every 3 months. Thus, in 100% of cases, there was an improvement in the visual field and visual acuity in all patients. Today there is no treatment for optic neuropathy worldwide. The antibacterial treatment of optic nerve atrophy implemented by us gives an effect in almost all cases. This treatment is based on creating a balance between the microbiota of the conjunctiva of the eyes and the antibodies surrounding them. The use of this method can significantly reduce the number of blind people in the world from optic nerve atrophy.